



CUTANEOUS T-CELL LYMPHOMA (CTCL):

A rare blood cancer seen on the skin

WHAT IS CTCL?

CTCL refers to a group of non-Hodgkin lymphomas that are derived from T-lymphocytes, a type of white blood cell. While CTCL is largely confined to the skin at diagnosis, it impacts each patient differently, with symptoms ranging from rash-like patches to thicker, itchy plaques and raised tumors. Despite ongoing research, the cause of CTCL remains unknown.¹⁻³



Annual incidence
6 in every 1,000,000

In the western world, the estimated annual incidence is approximately 6 in every 1,000,000.¹



Impacts twice as many men as women

CTCL is twice as common in men as in women.¹



CTCL increases with age

Risk for CTCL increases with age, and patients are typically diagnosed in their mid-50s.³

TYPES OF CTCL

CTCL includes a wide variety of different disorders. Among the various subtypes of CTCL are **mycosis fungoides** and **primary cutaneous CD30-positive lymphoproliferative disorders (LPDs)**. Overall survival rates for the disease have been shown to vary based on subtype, with 91% of patients with mycosis fungoides and between 75–100% with LPDs living for five years following diagnosis.⁴⁻⁷

Mycosis fungoides, named for the mushroom-like appearance of tumors, is the most common subtype and accounts for approximately 62% of all cases of CTCL.⁸ Typically slow-growing, mycosis fungoides is often localized to the skin. It can be present for long periods before diagnosis due to its resemblance to other conditions. There is variability among which patients express the CD30 protein, a tumor marker in various types of lymphoma.^{1,8-11}

LPDs are the second most common subgroup of CTCL and include primary cutaneous anaplastic large cell lymphoma (pcALCL) and different types of lymphomatoid papulosis (LyP). These cancers are characterized by cells that highly express CD30 and manifest as raised, red skin lesions, nodules or tumors.^{1,12,13}

DIAGNOSIS

Diagnosing CTCL in its earlier stages presents challenges, as lesions often resemble benign dermatitis. From the onset of symptoms, it can take an average of 5–6 years for patients to receive a diagnosis, and many are diagnosed by dermatologists rather than hematologists or oncologists.^{1,14} The following tests and procedures may be performed to diagnose CTCL:



Physical exam



Blood test



Biopsy
(skin and lymph nodes)



Screening tests
(CT scan, PET scan, MRI)

There is a need for improvements in diagnosis, including tests that can more easily identify CTCL in early stages through greater sensitivity and more specific biomarkers. Differentiating between subtypes via methods such as CD30 testing may help ensure patients receive the appropriate treatment.

TREATMENT OPTIONS

Due to the heterogeneity of CTCL, there is no single way to manage the disease. Patients with CTCL can receive skin-directed or systemic therapies, depending upon the stage of their disease; and, whilst there is no cure, remission has been achieved with stem cell transplant in a minority of eligible patients.¹⁵

Skin-directed therapies, used in earlier stage disease, include phototherapy, surgical excision, topical steroids, local radiotherapy, topical chemotherapies, and protection and moisturizing of the affected areas. In addition, topical antibiotics can be prescribed to treat infections associated with CTCL.^{1,2,16}

Systemic therapies may be used in patients with advanced CTCL and in those who do not respond well to skin-directed therapies. Biologics, immunotherapies, and chemotherapies are examples of systemic therapies, which target cancer at the cellular level.¹

For any treatment regimen used to treat patients with advanced CTCL, complete and durable responses are rare. Therapies are currently aimed at symptom control and improved quality of life.^{10,16,17}

1. Leukemia & Lymphoma Society. Cutaneous T-Cell Lymphoma Facts. Available at: https://www.lls.org/sites/default/files/file_assets/cutaneoustcelllymphoma.pdf (accessed February 2022).
2. Lymphoma Research Foundation. Understanding Cutaneous T-Cell Lymphoma. Available at: https://lymphoma.org/wp-content/uploads/2021/12/LRF-Cutaneous-T-Cell-Lymphoma_Factsheet.pdf (accessed February 2022).
3. Wilcox RA. *Am J Hematol* 2016;91:152–65.
4. Bradford PT et al. *Blood* 2009;113:5064–73.
5. Bekkenk MW et al. *Blood* 2000;95:3653–61.
6. Hapgood G et al. *Br J Haematol* 2017;176:234–40.
7. Wieser I et al. *J Dtsch Dermatol Ges* 2016;14:767–82.
8. Dobos G et al. *Cancers* 2020;12:2921.
9. Leukemia & Lymphoma Society. Cutaneous T-Cell Lymphoma. Available at: https://www.lls.org/sites/default/files/2021-05/PS96_CTCL_Booklet_Final.pdf (accessed February 2022).
10. Kim YH et al. *Eur J Cancer* 2021;148:411–21.
11. Prince HM. *J Clin Oncol* 2015;33:3691–6.
12. Prieto-Torres L et al. *Haematologica* 2019;104:226.
13. Cutaneous Lymphoma Foundation. Primary Cutaneous Anaplastic Large Cell Lymphoma. Available at: <https://www.clfoundation.org/primary-cutaneous-anaplastic-large-cell-lymphoma> (accessed February 2022).
14. Mishra A and Porcu P. *Blood* 2011;118:5717–18.
15. Kamijo H and Miyagaki T. *Curr Treat Options in Oncol* 2021;22:10. doi: 10.1007/s11864-020-00809-w.
16. National Comprehensive Cancer Network. Primary Cutaneous Lymphoma: NCCN Clinical Practice Guidelines in Oncology. Available at: <http://www.nccn.com> (accessed February 2022).
17. Whittaker S et al. *Blood* 2016;127:3142–53.

